Mobile

A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd) versus placebo in patients with type 2 diabetes and m...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-003723-21

A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd) versus placebo in patients with type 2 diabetes and moderate or severe renal insufficiency

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the safety and tolerability of vildagliptin (50 mg qd) vs. placebo in patients with T2DM and moderate or severe renal insufficiency over 24 weeks of treatment.

Critère d'inclusion

  • Diabetes Type 2 together with moderate or severe renal insufficiency

Liens